TOP - February 2016, Vol 9, No 1
Orlando, FL–New agents with novel targets have revolutionized management of chronic lymphocytic leukemia (CLL). However, all drugs have risks and benefits. At the 57th American Society of Hematology (ASH) Annual Meeting & Exposition, 3 separate presentations highlighted toxicity concerns related to idelalisib, ibrutinib, and venetoclax: hepatotoxicity with idelalisib, drug–drug interactions with ibrutinib, and the need for careful dosing at initiation of venetoclax.
In the February issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2015 Palliative Care in Oncology Symposium on aprepitant (Emend), a centrally acting neurokinin-1 antagonist indicated for patients with chemotherapy-induced nausea and vomiting.
All-Oral Combination Therapy Shows Promise in Patients with Transplant-Ineligible, Newly Diagnosed MM
An open-label, randomized, phase 2 study evaluated the all-oral triplet combination of ixazomib (an orally administered proteasome inhibitor) plus cyclophosphamide (at 2 different doses) and low-dose dexamethasone (ICd) as a 12-month induction therapy in previously untreated, transplant-ineligible patients with multiple myeloma (MM).
Presence of cytogenetic abnormalities (CAs) is considered to be an important prognostic factor in patients with multiple myeloma (MM), with some evidence suggesting that bortezomib-based combinations may overcome the poor prognosis associated with CAs, such as t(4;14), t(14;16), or deletion of 17p (del [17p]).
San Antonio, TX–A scalp cooling system protects against chemotherapy-induced hair loss in patients with breast cancer, and contributes to their well-being. The effects of the DigniCap scalp cooling system in 110 patients were presented at the 2015 San Antonio Breast Cancer Symposium.
Imatinib mesylate (IM) at 400 mg/day is the standard of care as first-line therapy in patients with newly diagnosed, chronic-phase chronic myeloid leukemia (CP-CML). Based on evidence that patients with high imatinib trough levels achieved higher rates of major molecular response (MMR), the randomized OPTIM-imatinib trial was conducted to evaluate the value of imatinib dose optimization according to imatinib Cmin levels in newly diagnosed patients with CP-CML.
Page 1 of 2
Results 1 - 10 of 19
Results 1 - 10 of 19